AssetMark Inc’s Spyre Therapeutics SYRE Stock Holding History

AssetMark Inc’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$644K	Buy	+7,232	New	+$695K	﹤0.01%	1186

Other funds holding SYRE

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

AssetMark Inc's SYRE Position: Q3 2026 in Review

AssetMark Inc opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 7,232 shares worth $644K. The stake represents ﹤0.01% of the portfolio and ranks #1186 among its holdings.

19 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

AssetMark Inc held 7,232 shares of Spyre Therapeutics worth $644K as of Q3 2026.
Spyre Therapeutics was a new AssetMark Inc position in Q3 2026.
Spyre Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1186 holding.
19 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.